Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 9
Submit an article Journal homepage
1,262
Views
227
CrossRef citations to date
0
Altmetric
Original Article

Population-based risk factors and resource utilization for HCC: US perspective

A. Sanyal Virginia Commonwealth University Healthcare System, Richmond, VA, USACorrespondence[email protected]
,
A. Poklepovic Virginia Commonwealth University Healthcare System, Richmond, VA, USA
,
E. Moyneur Statlog Consulting, Inc., L’Ange-Gardien, QC, Canada
&
V. Barghout Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA
Pages 2183-2191 | Accepted 02 Jul 2010, Published online: 29 Jul 2010

Citations (227)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Muhammad Imran Ahmad, Muhammad Umair Khan, Sudha Kodali, Akshay Shetty, S Michelle Bell & David Victor. (2022) Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma 9, pages 477-496.
Read now
Miaoguo Cai, Wei Shao, Huijun Yu, Ye Hong & Lili Shi. (2020) Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis. Cancer Management and Research 12, pages 5931-5943.
Read now
Luis Calzadilla Bertot & Leon A Adams. (2019) Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 13:2, pages 179-187.
Read now
Julius Balogh, David Victor$suffix/text()$suffix/text(), Emad H Asham, Sherilyn Gordon Burroughs, Maha Boktour, Ashish Saharia, Xian Li, R Mark Ghobrial & Howard P Monsour$suffix/text()$suffix/text(). (2016) Hepatocellular carcinoma: a review. Journal of Hepatocellular Carcinoma 3, pages 41-53.
Read now
Sohrab Rahimi Naini & Michael Fuchs. (2014) Non-alcoholic fatty liver disease in patients with diabetes mellitus. Expert Review of Endocrinology & Metabolism 9:5, pages 503-514.
Read now
Mohamed M Radwan, Basil M Radwan, Kalyana C Nandipati, William J Hunter$suffix/text()$suffix/text() & Devendra K Agrawal. (2013) Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Expert Review of Clinical Immunology 9:8, pages 727-738.
Read now

Articles from other publishers (221)

Vasileios Lekakis & George V. Papatheodoridis. (2023) Natural history of metabolic dysfunction-associated steatotic liver disease. European Journal of Internal Medicine.
Crossref
Akanksha DubeyJayanthi Sivaraman. (2023) Comparative Therapeutic Approaches for Hepatocellular Carcinoma-A Concise Review. Research Journal of Pharmacy and Technology, pages 4447-4454.
Crossref
Madalina-Gabriela Taru & Monica Lupsor-Platon. (2023) Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography. Cancers 15:16, pages 4097.
Crossref
Stergios A. Polyzos, Lampros Chrysavgis, Ilias D. Vachliotis, Evangelos Chartampilas & Evangelos Cholongitas. (2023) Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy. Seminars in Cancer Biology 93, pages 20-35.
Crossref
Maria Kotsari, Vassiliki Dimopoulou, John Koskinas & Athanasios Armakolas. (2023) Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression. International Journal of Molecular Sciences 24:14, pages 11471.
Crossref
Zhao-Yi Lin, Xiu-Ping Zhang, Guo-Dong Zhao, Cheng-Gang Li, Zhao-Hai Wang, Rong Liu & Ming-Gen Hu. (2023) Short-term outcomes of robotic versus open hepatectomy among overweight patients with hepatocellular carcinoma: a propensity score-matched study. BMC Surgery 23:1.
Crossref
Eliza W. Beal, Mackenzie Owen, Molly McNamara, Ann Scheck McAlearney & Allan Tsung. (2022) Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review. Journal of Gastrointestinal Cancer 54:2, pages 332-356.
Crossref
Ying Song, Beibei Wang, Wenjun Wang & Qiwen Shi. (2023) Regulatory effect of orexin system on various diseases through mTOR signaling pathway. Trends in Endocrinology & Metabolism 34:5, pages 292-302.
Crossref
Romain Donne & Amaia Lujambio. (2023) The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 77:5, pages 1773-1796.
Crossref
Ahan Bhatt & Jennifer Wu. (2023) Immunotherapy for recurrent hepatocellular carcinoma. World Journal of Gastroenterology 29:15, pages 2261-2271.
Crossref
Karim Seif El Dahan, Darine Daher & Amit G. Singal. (2023) Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease. Clinical and Molecular Hepatology 29:Suppl, pages S207-S219.
Crossref
Koen C. van Son, Lars Verschuren, Roeland Hanemaaijer, Helen Reeves, R. Bart Takkenberg, Joost P. H. Drenth, Maarten E. Tushuizen & Adriaan G. Holleboom. (2023) Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. Cancers 15:4, pages 1308.
Crossref
Mario M. Alba, Brandon Ebright, Brittney Hua, Ielyzaveta Slarve, Yiren Zhou, Yunyi Jia, Stan G. Louie & Bangyan L. Stiles. (2023) Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development. Frontiers in Physiology 14.
Crossref
Canxia Shi, Sanne de Wit, Emina Učambarlić, George Markousis-Mavrogenis, Elles Screever, Wouter Meijers, Rudolf de Boer & Joseph Aboumsallem. (2023) Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms. Cancers 15:3, pages 729.
Crossref
Lucia Cerrito, Irene Mignini, Maria Elena Ainora, Carolina Mosoni, Antonio Gasbarrini & Maria Assunta Zocco. (2023) Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. Cancers 15:3, pages 637.
Crossref
Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio V Dalla Riva, Edoardo G Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini & Fabio Farinati. (2023) Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut 72:1, pages 141-152.
Crossref
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho & Nguan Soon Tan. (2022) Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. International Journal of Molecular Sciences 24:1, pages 158.
Crossref
Lourianne Nascimento CAVALCANTE, Maria Gabriela Fernandes DEZAN, Cláudio Luiz da S L PAZ & André Castro LYRA. (2022) RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Arquivos de Gastroenterologia.
Crossref
Ioana Rusu, Radu Pirlog, Paul Chiroi, Andreea Nutu, Vlad Radu Puia, Alin Cornel Fetti, Daniel Radu Rusu, Ioana Berindan-Neagoe & Nadim Al Hajjar. (2022) The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. International Journal of Molecular Sciences 23:20, pages 12370.
Crossref
Jean-François Dufour, Quentin M Anstee, Elisabetta Bugianesi, Stephen Harrison, Rohit Loomba, Valerie Paradis, Herbert Tilg, Vincent Wai-Sun Wong & Shira Zelber-sagi. (2022) Current therapies and new developments in NASH. Gut 71:10, pages 2123-2134.
Crossref
Margit Mahlapuu, Mara Caputo, Ying Xia & Emmelie Cansby. (2022) GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond. Hepatology Communications 6:10, pages 2613-2622.
Crossref
Emma Hymel, Elizabeth Vlock, Kurt W. Fisher & Paraskevi A. Farazi. (2022) Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice. PLOS ONE 17:8, pages e0272623.
Crossref
Ahmed El Ray, Valerie Paradis, Ahmed Montasser, Maged Elghannam, Mohamed Shemis, Iris Nessim, Hoda Abu-Taleb, Tarik Asselah, Ashiq Mohamed, Nicolas Poté, Maha Akl & Patrick Marcellin. (2022) Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients. Egyptian Liver Journal 12:1.
Crossref
Ting Chen, Siwen Zhang, Dongmei Zhou, Peipei Lu, Xianglai Mo, Rashi Tamrakar & Xi Yang. (2022) Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma. Frontiers in Oncology 12.
Crossref
Lin Ru, Xiao-mei Wang & Jun-qi Niu. (2021) The miR-23–27–24 cluster: an emerging target in NAFLD pathogenesis. Acta Pharmacologica Sinica 43:5, pages 1167-1179.
Crossref
Doris Ogresta, Anna Mrzljak, Maja Cigrovski Berkovic, Ines Bilic-Curcic, Sanja Stojsavljevic-Shapeski & Lucija Virovic-Jukic. (2022) Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. Journal of Clinical and Translational Hepatology 10:2, pages 339-355.
Crossref
Balaji Musunuri, Shiran Shetty, Ganesh Bhat, Karthik Udupa & Ananth Pai. (2022) Profile of patients with hepatocellular carcinoma: An experience from a tertiary care center in India. Indian Journal of Gastroenterology 41:2, pages 127-134.
Crossref
Lampros Chrysavgis, Ilias Giannakodimos, Panagiota Diamantopoulou & Evangelos Cholongitas. (2022) Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World Journal of Gastroenterology 28:3, pages 310-331.
Crossref
Jiaye Liu, Ye Tian, Xia Fu, Chunyang Mu, Menglin Yao, Yinyun Ni, Yong Liu & Zhihui Li. (2022) Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis. Chinese Medical Journal 135:14, pages 1682-1691.
Crossref
Yeshwant Kurhe, Mara Caputo, Emmelie Cansby, Ying Xia, Sima Kumari, Sumit Kumar Anand, Brian W. Howell, Hanns-Ulrich Marschall & Margit Mahlapuu. (2022) Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. Cellular and Molecular Gastroenterology and Hepatology 13:2, pages 405-423.
Crossref
Bryan R. Chen & Calvin Q. Pan. (2022) Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. Clinics and Research in Hepatology and Gastroenterology 46:1, pages 101755.
Crossref
Amit G. Singal, Anna S. Lok, Ziding Feng, Fasiha Kanwal & Neehar D. Parikh. (2022) Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clinical Gastroenterology and Hepatology 20:1, pages 9-18.
Crossref
Sarojamma Vemula, Jeelan Basha Shaik, Amooru G. Damu & Ramakrishna Vadde. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 351 363 .
Richa Bajpai. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 153 165 .
Andrew T. DelaCourt & Anand S. Mehta. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology 112 125 .
Mignote Yilma, Varun Saxena & Neil Mehta. (2022) Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Current Gastroenterology Reports 24:1, pages 1-9.
Crossref
Lampros Chrysavgis, Grigorios Papadopoulos & Antonios Chatzigeorgiou. 2022.
Yuan-dong Sun, Hao Zhang, Ye-qiang Chen, Chun-xue Wu, Miao-ling Chen, Hui-rong Xu, Shuo Wang, Jing-zhou Liu & Jian-jun Han. (2021) Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1. BMC Cancer 21:1.
Crossref
Ying Xia, Mara Caputo, Emmelie Cansby, Sumit Kumar Anand, Silva Sütt, Marcus Henricsson, Rando Porosk, Hanns-Ulrich Marschall, Matthias Blüher & Margit Mahlapuu. (2021) STE20-type kinase TAOK3 regulates hepatic lipid partitioning. Molecular Metabolism 54, pages 101353.
Crossref
Ivica Grgurevic, Tonci Bozin, Mislav Mikus, Michal Kukla & James O’Beirne. (2021) Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers 13:22, pages 5844.
Crossref
Eun Jin Sun, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane & Lionel Hebbard. (2021) Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 9:11, pages 1639.
Crossref
Masatoshi Kudo. (2021) Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers 13:21, pages 5475.
Crossref
Marco Castellana, Rossella Donghia, Luisa Lampignano, Fabio Castellana, Roberta Zupo, Rodolfo Sardone, Giovanni De Pergola & Gianluigi Giannelli. (2021) Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. Journal of Clinical Medicine 10:20, pages 4638.
Crossref
Gustavo W. Fernandes & Barbara M. L. C. Bocco. (2021) Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes. Current Diabetes Reviews 17:7.
Crossref
Abigail E. Loneker & Rebecca G. Wells. (2021) Perspective: The Mechanobiology of Hepatocellular Carcinoma. Cancers 13:17, pages 4275.
Crossref
Jaskamal Padda, Khizer Khalid, Anwar Khedr, Fahriba Tasnim, Ola A Al-Ewaidat, Ayden Charlene Cooper & Gutteridge Jean-Charles. (2021) Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus.
Crossref
R. Paternostro, W. Sieghart, M. Trauner & M. Pinter. (2021) Cancer and hepatic steatosis. ESMO Open 6:4, pages 100185.
Crossref
Chien-Yu Lin, Pratik Adhikary & Kun Cheng. (2021) Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. Advanced Drug Delivery Reviews 174, pages 127-139.
Crossref
Xiujing Sun, Shengtao Zhu, Xueyu Dong, Runar J. Strand-Amundsen, Tor Inge Tonnessen & Runkuan Yang. (2021) Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis. Biomedicine & Pharmacotherapy 137, pages 111392.
Crossref
Jiayun Ge, Yannan Bai, Bo Tang, Dong Wei & Maolin Yan. (2021) The Gene Signature Associated with Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Journal of Oncology 2021, pages 1-9.
Crossref
Ahmed Hashem, Yogesh Shastri, Malfi Al Otaibi, Elwin Buchel, Hussam Saleh, Reyaz Ahmad, Hamouda Ahmed, Fateh Al Idris, Saleh Ahmed, Mohamed Guda & Anton Gillessen. (2021) Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin. Gastroenterology Insights 12:2, pages 155-165.
Crossref
Daniel Q. Huang, Hashem B. El-Serag & Rohit Loomba. (2020) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology 18:4, pages 223-238.
Crossref
Miriam Longo, Marica Meroni, Erika Paolini, Chiara Macchi & Paola Dongiovanni. (2021) Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. Metabolism 117, pages 154708.
Crossref
Kenji Imai, Koji Takai, Takao Miwa, Toshihide Maeda, Tatsunori Hanai, Makoto Shiraki, Atsushi Suetsugu & Masahito Shimizu. (2021) Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment. Cancers 13:7, pages 1542.
Crossref
Minting Chen, Haitao Xiao, Baisen Chen, Zhaoxiang Bian & Hiu Yee Kwan. (2021) The advantages of using Scutellaria baicalensis and its flavonoids for the management of non-viral hepatocellular carcinoma. Journal of Functional Foods 78, pages 104389.
Crossref
Béatrice Morio, Baptiste Panthu, Arthur Bassot & Jennifer Rieusset. (2021) Role of mitochondria in liver metabolic health and diseases. Cell Calcium 94, pages 102336.
Crossref
Moritz Peiseler & Frank Tacke. (2021) Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers 13:4, pages 730.
Crossref
Mojun Zhu, Zhaohui Jin & Joleen M. Hubbard. (2021) Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers 13:4, pages 651.
Crossref
Erin Wolf, Nicole E. Rich, Jorge A. Marrero, Neehar D. Parikh & Amit G. Singal. (2020) Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐Analysis. Hepatology 73:2, pages 713-725.
Crossref
Maysa A. Mobasher, Mousa O. Germoush, Hala Galal El-Tantawi & Karim Samy El-Said. (2021) Metformin Improves Biochemical and Pathophysiological Changes in Hepatocellular Carcinoma with Pre-Existed Diabetes Mellitus Rats. Pathogens 10:1, pages 59.
Crossref
Mingfeng Xia, Preethi Chandrasekaran, Shunxing Rong, Xiaorong Fu & Matthew A. Mitsche. (2021) Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver. Journal of Lipid Research 62, pages 100031.
Crossref
Masatoshi Kudo. (2021) Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?. Liver Cancer 10:4, pages 289-295.
Crossref
Matthias Pinter, Bernhard Scheiner & Markus Peck-Radosavljevic. (2021) Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 70:1, pages 204-214.
Crossref
Michele Molinari, Christof Kaltenmeier, Patrick-Bou Samra, Hao Liu, Charles Wessel, Mary Lou Klem, Stalin Dharmayan, Bishoy Emmanuel, Hasan Al Harakeh, Samer Tohme, David Geller, Amit Tevar, Christopher B. Hughes, Abhinav Humar, Ramon Bataller & Jaideep Behari. (2021) Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Annals of Surgery Open 2:2, pages e065.
Crossref
Eduardo Vilar-Gomez, Luis Calzadilla-Bertot, Vincent Wai-Sun Wong, Marlen Castellanos, Rocio Aller-de la Fuente, Mohammed Eslam, Grace Lai-Hung Wong, Jacob George, Manuel Romero-Gomez & Leon A. Adams. (2021) Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis. Clinical Gastroenterology and Hepatology 19:1, pages 136-145.e6.
Crossref
Sanaa Kamal. 2021. Liver Cancer in the Middle East. Liver Cancer in the Middle East 299 311 .
Pierre Nahon, Manon Allaire, Jean-Charles Nault & Valérie Paradis. (2020) Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepatic Oncology 7:4.
Crossref
Yohei Kamata, Takaomi Kessoku, Tomoko Shimizu, Takashi Kobayashi, Takeo Kurihashi, Satsuki Sato, Syotaro Kuraji, Norio Aoyama, Tomoyuki Iwasaki, Shogo Takashiba, Nobushiro Hamada, Toshiro Kodama, Toshiyuki Tamura, Satoshi Ino, Takuma Higurashi, Masataka Taguri, Takeharu Yamanaka, Masato Yoneda, Haruki Usuda, Koichiro Wada, Atsushi Nakajima & Masato Minabe. (2020) Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials 21:1.
Crossref
Lisa X. Deng & Neil Mehta. (2020) Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Digestive Diseases and Sciences 65:12, pages 3456-3462.
Crossref
Feizhou Huang, Huaizheng Liu, Zhao Lei, Zhenzhou Li, Tianyi Zhang, Mingshi Yang, Kefu Zhou & Chuanzheng Sun. (2020) Long noncoding RNA CCAT1 inhibits miR‐613 to promote nonalcoholic fatty liver disease via increasing LXRα transcription . Journal of Cellular Physiology 235:12, pages 9819-9833.
Crossref
Kunimaro Furuta, Qianqian Guo, Petra Hirsova & Samar H. Ibrahim. (2020) Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis. Biology 9:11, pages 395.
Crossref
Monica Lupsor-Platon, Teodora Serban, Alexandra-Iulia Silion, Alexandru Tirpe & Mira Florea. (2020) Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers 12:10, pages 2778.
Crossref
Abdalla Aly, Sarah Ronnebaum, Dipen Patel, Yunes Doleh & Fernando Benavente. (2020) Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepatic Oncology 7:3.
Crossref
Leon A Adams, Stuart K Roberts, Simone I Strasser, Suzanne E Mahady, Elizabeth Powell, Chris Estes, Homie Razavi & Jacob George. (2020) Nonalcoholic fatty liver disease burden: Australia, 2019–2030. Journal of Gastroenterology and Hepatology 35:9, pages 1628-1635.
Crossref
Seo-Young Koo, Eun-Ji Park & Chang-Woo Lee. (2020) Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Experimental & Molecular Medicine 52:8, pages 1209-1219.
Crossref
Winston E. Abara, P. Spradling, Y. Zhong, A. Moorman, E. H. Teshale, L. Rupp, S. C. Gordon, M. Schmidt, J. A. Boscarino, Y. G. Daida & S. D. Holmberg. (2019) Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. Journal of Gastrointestinal Cancer 51:2, pages 461-468.
Crossref
Thevaraajan Jayaraman, Yeong‐Yeh Lee, Wah‐Kheong Chan & Sanjiv Mahadeva. (2019) Epidemiological differences of common liver conditions between Asia and the West. JGH Open 4:3, pages 332-339.
Crossref
Maria Corina Plaz Torres, Giorgia Bodini, Manuele Furnari, Elisa Marabotto, Patrizia Zentilin, Mario Strazzabosco & Edoardo G. Giannini. (2020) Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. Cancers 12:6, pages 1422.
Crossref
Muhammed Majeed, Shaheen Majeed, Kalyanam Nagabhushanam, Lincy Lawrence & Lakshmi Mundkur. (2020) Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Scientific Reports 10:1.
Crossref
Mark G. Swain, Alnoor Ramji, Keyur Patel, Giada Sebastiani, Abdel Aziz Shaheen, Edward Tam, Paul Marotta, Magdy Elkhashab, Harpreet S. Bajaj, Chris Estes & Homie Razavi. (2020) Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study. CMAJ Open 8:2, pages E429-E436.
Crossref
Marie Lequoy, Elia Gigante, Jean-Pierre Couty & Christèle Desbois-Mouthon. (2020) Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Hormone Molecular Biology and Clinical Investigation 41:1.
Crossref
Francesco Negro. (2020) Natural history of NASH and HCC. Liver International 40:S1, pages 72-76.
Crossref
Kanehiko Suwa, Takashi Yamaguchi, Katsunori Yoshida, Miki Murata, Mayuko Ichimura, Koichi Tsuneyama, Toshihito Seki & Kazuichi Okazaki. (2020) Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis. Cancers 12:2, pages 286.
Crossref
Xiao-yan Shi, Si-min Fan, Guo-mei Shi, Jia Yao, Yang Gao, Yu-guo Xia & Qiu Chen. (2020) Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease. Medicine 99:24, pages e20624.
Crossref
Yasmeen M. Attia, Heba Ewida & Mahmoud Salama Ahmed. 2020. Drug Repurposing in Cancer Therapy. Drug Repurposing in Cancer Therapy 213 229 .
Alisa Likhitsup & Neehar D. Parikh. (2019) Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. PharmacoEconomics 38:1, pages 5-24.
Crossref
Gregory H. Underhill & Salman R. Khetani. (2019) Emerging trends in modeling human liver disease in vitro . APL Bioengineering 3:4.
Crossref
Doris Kaltenecker, Madeleine Themanns, Kristina M. Mueller, Katrin Spirk, Tobias Suske, Olaf Merkel, Lukas Kenner, Andreia Luís, Andrey Kozlov, Johannes Haybaeck, Mathias Müller, Xiaonan Han & Richard Moriggl. (2019) Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine 124, pages 154569.
Crossref
Fabienne Rajas, Amandine Gautier-Stein & Gilles Mithieux. (2019) Glucose-6 Phosphate, a Central Hub for Liver Carbohydrate Metabolism. Metabolites 9:12, pages 282.
Crossref
Mélissa Léveillé & Jennifer L. Estall. (2019) Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 9:10, pages 233.
Crossref
Ming-Feng Xia, Hua Bian & Xin Gao. (2019) NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Frontiers in Pharmacology 10.
Crossref
Yanan Zhang, Chunguang Wang, Hongqin Xu, Peng Xiao & Yanhang Gao. (2019) Hepatocellular carcinoma in the noncirrhotic liver: a literature review. European Journal of Gastroenterology & Hepatology 31:7, pages 743-748.
Crossref
Quentin M. Anstee, Helen L. Reeves, Elena Kotsiliti, Olivier Govaere & Mathias Heikenwalder. (2019) From NASH to HCC: current concepts and future challenges. Nature Reviews Gastroenterology & Hepatology 16:7, pages 411-428.
Crossref
Arun J. Sanyal. (2019) Past, present and future perspectives in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology 16:6, pages 377-386.
Crossref
Vaibhav Chand, Akshay Pandey, Dragana Kopanja, Grace Guzman & Pradip Raychaudhuri. (2019) Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer. Molecular Cancer Research 17:5, pages 1063-1074.
Crossref
Joe L. RowlesIIIIII, Aiguo Han, Rita J. Miller, Jamie R. Kelly, Catherine C. Applegate, Matthew A. Wallig, William D. O’BrienJrJr & John W. ErdmanJrJr. (2019) Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method. Nutrition Research 63, pages 95-105.
Crossref
Okeefe L. Simmons, Yuan Feng, Neehar D. Parikh & Amit G. Singal. (2019) Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. Clinical Gastroenterology and Hepatology 17:4, pages 766-773.
Crossref
Hsien Min Low, Jin Young Choi & Cher Heng Tan. (2018) Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. Abdominal Radiology 44:2, pages 493-508.
Crossref
Rogério Camargo-Pinheiro-Alves, Daniele E. Viera-Alves, Arthur Malzyner, Otavio Gampel, Thaisa de F. Almeida-Costa, Betty Guz & Paula Poletti. (2019) Experience with Sorafenib in 3 Hospitals in Sao Paulo. Annals of Hepatology 18:1, pages 172-176.
Crossref
Marie Liebig, Dirk Dannenberger, Brigitte Vollmar & Kerstin Abshagen. (2019) n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model. Therapeutic Advances in Chronic Disease 10, pages 204062231987211.
Crossref
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel & J.A. Velarde-Ruiz Velasco. (2019) The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 84:1, pages 69-99.
Crossref
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel & J.A. Velarde-Ruiz Velasco. (2019) Consenso mexicano de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 84:1, pages 69-99.
Crossref
Osmanuddin Ahmed, Lisa Liu, Antony Gayed, Amanjit Baadh, Mikin Patel, Jordan Tasse, Ulku Turba & Bulent Arslan. (2019) The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis. Journal of Clinical and Experimental Hepatology 9:1, pages 50-55.
Crossref
Daniel L. Hurley. 2019. Bariatric Endocrinology. Bariatric Endocrinology 293 323 .
Duminda Suraweera, Peter Konyn, Thomas Vu & Sammy Saab. 2019. Clinical Epidemiology of Chronic Liver Diseases. Clinical Epidemiology of Chronic Liver Diseases 229 249 .
Cristiane A. Villela Nogueira & Nathalie Carvalho Leite. 2019. The Diabetes Textbook. The Diabetes Textbook 227 235 .
Felice De Stefano, Eduardo Chacon, Lilia Turcios, Francesc Marti & Roberto Gedaly. (2018) Novel biomarkers in hepatocellular carcinoma. Digestive and Liver Disease 50:11, pages 1115-1123.
Crossref
Chris Estes, Quentin M. Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P. Day, Yuichiro Eguchi, Andreas Geier, Loreta A. Kondili, Daniela C. Kroy, Jeffrey V. Lazarus, Rohit Loomba, Michael P. Manns, Giulio Marchesini, Atsushi Nakajima, Francesco Negro, Salvatore Petta, Vlad Ratziu, Manuel Romero-Gomez, Arun Sanyal, Jörn M. Schattenberg, Frank Tacke, Junko Tanaka, Christian Trautwein, Lai Wei, Stefan Zeuzem & Homie Razavi. (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology 69:4, pages 896-904.
Crossref
Tianpeng Jiang, Zhi Huang, Shuai Zhang, Weijie Zou, Lei Xiang, Xiaowen Wu, Yaping Shen, Weixin Liu, Zhu Zeng, Ansu Zhao, Shi Zhou & Qingfan Zeng. (2018) miR‑23b inhibits proliferation of SMMC‑7721 cells by directly targeting IL‑11. Molecular Medicine Reports.
Crossref
Hussein F Aqbi, Matthew Wallace, Samay Sappal, Kyle K Payne & Masoud H Manjili. (2018) IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. Journal of Leukocyte Biology 103:6, pages 1219-1223.
Crossref
Paula Iruzubieta, Marta González, Joaquín Cabezas, María Teresa Arias-Loste & Javier Crespo. 2018. Liver Research and Clinical Management. Liver Research and Clinical Management.
Tracey G. Simon, Lindsay Y. King, Dawn Q. Chong, Long H. Nguyen, Yanan Ma, Trang VoPham, Edward L. Giovannucci, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Hamed Khalili, Raymond T. Chung, Xuehong Zhang & Andrew T. Chan. (2018) Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 67:5, pages 1797-1806.
Crossref
Erin M. Sadler, Neil Mehta, Mamatha Bhat, Anand Ghanekar, Paul D. Greig, David R. Grant, Francis Yao & Gonzalo Sapisochin. (2018) Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation 102:4, pages 640-647.
Crossref
Keisha Bonner & Julie K. Heimbach. (2018) Obesity management in the liver transplant recipient. Current Opinion in Organ Transplantation 23:2, pages 244-249.
Crossref
Natalie H. Bzowej. (2018) Nonalcoholic steatohepatitis. Current Opinion in Organ Transplantation 23:2, pages 169-174.
Crossref
Christopher D. Woodrell, Lissi Hansen, Thomas D. Schiano & Nathan E. Goldstein. (2018) Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. Clinical Therapeutics 40:4, pages 512-525.
Crossref
Shoji Yamada, Yoko Takashina, Mitsuhiro Watanabe, Ryogo Nagamine, Yoshimasa Saito, Nobuhiko Kamada & Hidetsugu Saito. (2018) Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 9:11, pages 9925-9939.
Crossref
Ramy Younes & Elisabetta Bugianesi. (2018) Should we undertake surveillance for HCC in patients with NAFLD?. Journal of Hepatology 68:2, pages 326-334.
Crossref
Pasquale Agosti, Carlo Sabbà & Antonio Mazzocca. (2018) Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:2, pages 607-617.
Crossref
Shoji Yamada, Masaki Kimura, Yoshimasa Saito & Hidetsugu Saito. (2018) Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. Journal of Clinical Biochemistry and Nutrition 63:2, pages 123-128.
Crossref
David E. Kaplan, Rajni Mehta, Kathryn D’Addeo, Adriana Valderrama & Tamar H. Taddei. (2018) Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 97:4, pages e9757.
Crossref
Vlad Ratziu. (2018) The painful reality of end-stage liver disease in NASH. The Lancet Gastroenterology & Hepatology 3:1, pages 8-10.
Crossref
Quentin M. Anstee & Christopher P. Day. 2018. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology 391 405.e3 .
An Tang, Oussama Hallouch, Victoria Chernyak, Aya Kamaya & Claude B. Sirlin. (2017) Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdominal Radiology 43:1, pages 13-25.
Crossref
György Baffy. 2018. Obesity, Fatty Liver and Liver Cancer. Obesity, Fatty Liver and Liver Cancer 63 77 .
Lucija Virović-Jukić, Jelena Forgač, Doris Ogresta, Tajana Filipec-Kanižaj & Anna Mrzljak. 2018. Gastrointestinal Complications of Diabetes. Gastrointestinal Complications of Diabetes 275 315 .
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi & Arun J. Sanyal. (2017) Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67:1, pages 123-133.
Crossref
R. Pais, L. Fartoux, C. Goumard, O. Scatton, D. Wendum, O. Rosmorduc & V. Ratziu. (2017) Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Alimentary Pharmacology & Therapeutics 46:9, pages 856-863.
Crossref
Camille Teilhet, Daniel Morvan, Juliette Joubert-Zakeyh, Anne-Sophie Biesse, Bruno Pereira, Sylvie Massoulier, Pierre Dechelotte, Denis Pezet, Emmanuel Buc, Géraldine Lamblin, Michel Peoc’h, Jack Porcheron, Marie-Paule Vasson, Armando Abergel & Aicha Demidem. (2017) Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts 1H-NMR Spectroscopy. Metabolites 7:4, pages 49.
Crossref
David G. Koch. (2017) Screening for Hepatocellular Carcinoma in Patients with Cirrhosis: A Need to Increase Awareness. The American Journal of Medicine 130:9, pages 1007-1008.
Crossref
Amit G. Singal, Jasmin Tiro, Xilong Li, Beverley Adams-Huet & Jessica Chubak. (2017) Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. Journal of Clinical Gastroenterology 51:7, pages 650-655.
Crossref
Xinhui Liu, Feiye Liu, Shenglan Gao, Jake Reske, Aimin Li, Chin-Lee Wu, Chengfeng Yang, Fengsheng Chen, Rongcheng Luo & Hua Xiao. (2017) A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer Letters 391, pages 152-161.
Crossref
Sandra R. Almeida-Carvalho, Maria L. Gomes-Ferraz, Carla A. Loureiro-Matos, Antônio E. Benedito-Silva, Roberto J. Carvalho-Filho, Rogério Renato-Perez, Adriano Miziara-Gonzalez, Alcides A. Salzedas-Netto, Denis Szejnfeld, Giuseppe D’Ippolito, Valéria Pereira-Lanzoni & Ivonete S. Souza-Silva. (2017) Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil. Annals of Hepatology 16:2, pages 255-262.
Crossref
Behnam Rabiee, Farzin Roozafzai, Gholam Reza Hemasi, Hossein Poustchi, Hossein Keyvani, Mahmood Reza Khonsari, Hossein Ajdarkosh, Mansooreh Maadi, Fatemeh Sima Saeedian & Farhad Zamani. (2017) The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East Journal of Digestive Diseases 9:2, pages 86-93.
Crossref
Shamir Cassim, Marc Bilodeau, Catherine Vincent & Pascal Lapierre. (2017) Novel Immunotherapies for Autoimmune Hepatitis. Frontiers in Pediatrics 5.
Crossref
Abdul M. Oseini & Arun J. Sanyal. (2017) Therapies in non-alcoholic steatohepatitis (NASH). Liver International 37, pages 97-103.
Crossref
Julie Heimbach. (2016) Surgical advances in obese candidates and recipients. Liver Transplantation 22:S1, pages 62-67.
Crossref
Christian Dominik Fingas, Jan Best, Jan-Peter Sowa & Ali Canbay. (2016) Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. Clinical Liver Disease 8:5, pages 119-122.
Crossref
Nwe Ni Than, Anwar Ghazanfar, James Hodson, Nadeem Tehami, Chris Coldham, Hynek Mergental, Derek Manas, Tahir Shah, Philip N Newsome, Helen Reeves & Shishir Shetty. (2016) Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM, pages hcw151.
Crossref
Jella-Andrea Abraham & Olga Golubnitschaja. (2016) Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. Personalized Medicine 13:5, pages 455-467.
Crossref
Bashar Mohamad, Vaishal Shah, Mykola Onyshchenko, Mohammed Elshamy, Federico Aucejo, Rocio Lopez, Ibrahim A. Hanouneh, Razan Alhaddad & Naim Alkhouri. (2015) Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology International 10:4, pages 632-639.
Crossref
Arun J. Sanyal & Veronica Miller. (2016) Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis. Gastroenterology 150:8, pages 1723-1727.
Crossref
Anna Simona Sasdelli, Lucia Brodosi & Giulio Marchesini. (2016) NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Current Hepatology Reports 15:2, pages 103-112.
Crossref
Way Siow, David van der Poorten & Jacob George. (2016) Epidemiological Trends in NASH as a Cause for Liver Transplant. Current Hepatology Reports 15:2, pages 67-74.
Crossref
Shao-Ru Chen, Hong-Cong Qiu, Yang Hu, Ying Wang & Yi-Tao Wang. (2016) Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma. Phytotherapy Research 30:6, pages 863-877.
Crossref
Timothy HardyFiona OakleyQuentin M. AnsteeChristopher P. Day. (2016) Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease 11:1, pages 451-496.
Crossref
Andrea Marengo, Ramy Ibrahim Kamal Jouness & Elisabetta Bugianesi. (2016) Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clinics in Liver Disease 20:2, pages 313-324.
Crossref
Helen L. Reeves, Marco Y. W. Zaki & Christopher P. Day. (2016) Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Digestive Diseases and Sciences 61:5, pages 1234-1245.
Crossref
Lung-Yi Lee & David P. Foley. (2016) Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular Carcinoma. Surgical Clinics of North America 96:2, pages 269-281.
Crossref
Andrea MarengoChiara RossoElisabetta Bugianesi. (2016) Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annual Review of Medicine 67:1, pages 103-117.
Crossref
Ivana Mikolasevic, Lidija Orlic, Neven Franjic, Goran Hauser, Davor Stimac & Sandra Milic. (2016) Transient elastography (FibroScan ® ) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? . World Journal of Gastroenterology 22:32, pages 7236.
Crossref
Sahil Mittal, Hashem B. El-Serag, Yvonne H. Sada, Fasiha Kanwal, Zhigang Duan, Sarah Temple, Sarah B. May, Jennifer R. Kramer, Peter A. Richardson & Jessica A. Davila. (2016) Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 14:1, pages 124-131.e1.
Crossref
Fabio Nascimbeni & Vlad Ratziu. 2016. Alcoholic and Non-Alcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease 271 290 .
David E. Kleiner & Pierre Bedossa. (2015) Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. Gastroenterology 149:6, pages 1305-1308.
Crossref
Chuanzheng Sun, Xunyang Liu, Zhongjie Yi, Xuefei Xiao, Mingshi Yang, Gui Hu, Huaizheng Liu, Liangkan Liao & Feizhou Huang. (2015) Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. IUBMB Life 67:11, pages 847-852.
Crossref
Münevver Demir, Sonja Lang & Hans‐Michael Steffen. (2015) Nonalcoholic fatty liver disease – current status and future directions. Journal of Digestive Diseases 16:10, pages 541-557.
Crossref
Ryan B. Schwope, Lauren A. May, Michael J. Reiter, Christopher J. Lisanti & Daniel J. A. Margolis. (2015) Gadoxetic acid: pearls and pitfalls. Abdominal Imaging 40:6, pages 2012-2029.
Crossref
Kirti Shetty, Jian Chen, Ji-hyun Shin, Wilma Jogunoori & Lopa Mishra. (2015) Pathogenesis of Hepatocellular Carcinoma Development in Non-alcoholic Fatty Liver Disease. Current Hepatology Reports 14:2, pages 119-127.
Crossref
Sahil Mittal, Donna L. White, Fasiha Kanwal, Norman Sussman & Hashem B. El-Serag. (2015) Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?. Current Hepatology Reports 14:2, pages 87-98.
Crossref
Arun J. Sanyal. (2015) Future watch: Evolving trends in the management of nonalcoholic steatohepatitis. Clinical Liver Disease 5:6, pages 139-141.
Crossref
Bérénice Charrez, Liang Qiao & Lionel Hebbard. (2015) The role of fructose in metabolism and cancer. Hormone Molecular Biology and Clinical Investigation 22:2, pages 79-89.
Crossref
Timothy Hardy, Quentin M. Anstee & Christopher P. Day. (2015) Nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 31:3, pages 175-183.
Crossref
Mazen Noureddin & Mary E. Rinella. (2015) Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma. Clinics in Liver Disease 19:2, pages 361-379.
Crossref
Raluca Pais, Pascal Lebray, Geraldine Rousseau, Frédéric Charlotte, Ghizlaine Esselma, Eric Savier, Dominique Thabut, Marika Rudler, Daniel Eyraud, Corinne Vezinet, Jean-Michel Siksik, Jean-Christophe Vaillant, Laurent Hannoun, Thierry Poynard & Vlad Ratziu. (2015) Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. Clinical Gastroenterology and Hepatology 13:5, pages 992-999.e2.
Crossref
Mariana Lazo, Jonathan Rubin, Jeanne M. Clark, Josef Coresh, Andrea L.C. Schneider, Chiadi Ndumele, Ron C. Hoogeveen, Christie M. Ballantyne & Elizabeth Selvin. (2015) The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. Journal of Hepatology 62:4, pages 841-847.
Crossref
Christopher E. McGowan, Teresa P. Edwards, Mai-Uyen T. Luong & Paul H. Hayashi. (2015) Suboptimal Surveillance for and Knowledge of Hepatocellular Carcinoma Among Primary Care Providers. Clinical Gastroenterology and Hepatology 13:4, pages 799-804.
Crossref
Eimile Dalton-Fitzgerald, Jasmin Tiro, Pragathi Kandunoori, Ethan A. Halm, Adam Yopp & Amit G. Singal. (2015) Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology 13:4, pages 791-798.e1.
Crossref
Arun J. Sanyal, Scott L. Friedman, Arthur J. McCullough & Lara Dimick‐Santos. (2015) Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop. Hepatology 61:4, pages 1392-1405.
Crossref
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed, Kris V Kowdley, Arthur McCullough, Norah Terrault, Jeanne M Clark, James Tonascia, Elizabeth M Brunt, David E Kleiner & Edward Doo. (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet 385:9972, pages 956-965.
Crossref
Kohei Oda, Hirofumi Uto, Seiichi Mawatari & Akio Ido. (2015) Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clinical Journal of Gastroenterology 8:1, pages 1-9.
Crossref
Christopher Leung. (2015) Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World Journal of Gastroenterology 21:4, pages 1189.
Crossref
Letiția Adela Maria Streba. (2015) Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question. World Journal of Gastroenterology 21:14, pages 4103.
Crossref
Arun J. Sanyal. (2015) Use of Farnesoid X Receptor Agonists to Treat Nonalcoholic Fatty Liver Disease. Digestive Diseases 33:3, pages 426-432.
Crossref
Rim Serhal, George Hilal, George Boutros, Joseph Sidaoui, Layal Wardi, Salah Ezzeddine & Nada Alaaeddine. (2015) Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. BioMed Research International 2015, pages 1-9.
Crossref
Amit G. Singal, Xilong Li, Jasmin Tiro, Pragathi Kandunoori, Beverley Adams-Huet, Mahendra S. Nehra & Adam Yopp. (2015) Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. The American Journal of Medicine 128:1, pages 90.e1-90.e7.
Crossref
Bubu A. Banini & Lewis R. Roberts. 2015. Complications of Cirrhosis. Complications of Cirrhosis 207 218 .
Kyle J. Thompson, John R. Humphries, David J. Niemeyer, David Sindram & Iain H. McKillop. 2015. Biological Basis of Alcohol-Induced Cancer. Biological Basis of Alcohol-Induced Cancer 361 373 .
Julie Heimbach. (2014) Debate: A bridge too far-liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. Liver Transplantation 20:S2, pages S32-S37.
Crossref
A He & Lopa Mishra. 2014. Liver Metabolism and Fatty Liver Disease. Liver Metabolism and Fatty Liver Disease 53 78 .
Arun J. Sanyal, Manal F. Abdelmalek, Ayako Suzuki, Oscar W. Cummings & Mario Chojkier. (2014) No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology 147:2, pages 377-384.e1.
Crossref
Dipanjan Panda. (2014) Role of Surveillance in Prevention of Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology 4, pages S43-S49.
Crossref
Y.-L. Liu, G.L. Patman, J.B.S. Leathart, A.-C. Piguet, A.D. Burt, J.-F. Dufour, C.P. Day, A.K. Daly, H.L. Reeves & Q.M. Anstee. (2014) Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology 61:1, pages 75-81.
Crossref
Ester Vanni, Lavinia Mezzabotta & Elisabetta Bugianesi. (2014) NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really?. Current Hepatology Reports 13:2, pages 113-118.
Crossref
Raffi Karagozian, Zoltán Derdák & György Baffy. (2014) Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63:5, pages 607-617.
Crossref
Xiao-Yan Duan, Lei Zhang, Jian-Gao Fan & Liang Qiao. (2014) NAFLD leads to liver cancer: Do we have sufficient evidence?. Cancer Letters 345:2, pages 230-234.
Crossref
Ying Ding, Sheng-Xiang Rao, Tao Meng, Caizhong Chen, Renchen Li & Meng-Su Zeng. (2014) Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. European Radiology 24:4, pages 959-966.
Crossref
Ta-Chiang Liu, Neeta Vachharajani, William C Chapman & Elizabeth M Brunt. (2014) Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Modern Pathology 27:3, pages 420-432.
Crossref
Ester Vanni & Elisabetta Bugianesi. (2014) Obesity and Liver Cancer. Clinics in Liver Disease 18:1, pages 191-203.
Crossref
Mingqian Feng & Mitchell Ho. (2014) Glypican-3 antibodies: A new therapeutic target for liver cancer. FEBS Letters 588:2, pages 377-382.
Crossref
Jae Youn Cheong. (2014) Is It Necessary for NAFLD Patients to be Screened for Hepatocellular Carcinoma?. The Korean Journal of Gastroenterology 63:5, pages 265.
Crossref
Chun-Meng Jiang. (2014) Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World Journal of Gastroenterology 20:44, pages 16464.
Crossref
Seth M. CohenJaewhan KimNelson RoyMark Courey. (2013) Factors influencing referral of patients with voice disorders from primary care to otolaryngology. The Laryngoscope 124:1, pages 214-220.
Crossref
Rohit Loomba & Arun J. Sanyal. (2013) The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology 10:11, pages 686-690.
Crossref
D. Tan, A. Yopp, M. S. Beg, P. Gopal & A. G. Singal. (2013) Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Alimentary Pharmacology & Therapeutics 38:7, pages 703-712.
Crossref

Displaying 200 of 227 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.